HZNQF HORIZON DISCOVERY GROUP PLC

Horizon Discovery and Rutgers University form exclusive partnership to develop next generation novel gene editing technology

Horizon Discovery and Rutgers University form exclusive partnership to develop next generation novel gene editing technology

Horizon Discovery Group plc

Horizon Discovery and Rutgers University form exclusive partnership to develop next generation novel gene editing technology

  • Horizon will work with Rutgers University to develop and commercialise base editing platform for therapeutic and research applications
  • New gene editing technology builds on CRISPR and has the potential to assist in the development and treatment of a number of genetic diseases and cancers

             

Cambridge, UK, 28 January 2019: Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Group”), a global leader in gene editing and gene modulation technologies, today announces that it has entered into an exclusive strategic partnership with Rutgers, The State University of New Jersey (US), to develop and commercialise a novel gene editing technology, known as base editing. The technology potentially has applications in the development of new cell therapies and will augment Horizon’s research tools and services.

Horizon will collaborate with Rutgers University to further develop the novel base editing platform from the laboratory of Dr. Shengkan Jin, associate professor of pharmacology at Rutgers Robert Wood Johnson Medical School. As part of the agreement, Horizon has made a non-material payment to Rutgers for an option to exclusively license the base editing technology for use in all therapeutic applications. As part of the collaboration, Horizon will also fund further research in base editing at Rutgers University while undertaking evaluation and proof of concept studies at Horizon. 

Base editing is a novel technology platform for engineering DNA or genes in cells that has the potential to correct errors or mutations in the DNA by modifying genes using an enzyme. Compared with currently available gene editing methodologies such as CRISPR/Cas9, which creates “cuts” in the gene that can lead to adverse or negative effects, this new technology allows for more accurate gene editing while reducing unintended genomic changes. The technology will have a significant impact in enabling cell therapies to be progressed through clinical development and towards commercialisation. For more scientific detail on base editing, please see below in the notes to editors.

Terry Pizzie, Horizon’s Chief Executive Officer, said: “Base editing is potentially transformative for all gene editing technologies with the potential to help target many diseases that to date have no treatment. As a world leader in the field of gene editing and gene modulation, both in research and applied markets, we are very excited to partner with Dr Jin and Rutgers University. By extending our scientific and IP capabilities, Horizon will now be able to more fully support our pharma, biotech and academic partners to deliver better cell therapy solutions to patients. As part of our five-year investment strategy, Horizon committed to investing in high value technologies that maintain our market leadership; base editing technology is a perfect example of that. We look forward to updating on the progress of the partnership and potential future next steps.”

Dr. Shengkan ‘Victor’ Jin of Rutgers University stated: “The cytidine deaminase version of the technology alone could potentially be used for developing ex vivo therapeutics such as gene modified cells for sickle cell anemia and beta thalassemia, HIV resistant cells for AIDS, and over-the-shelf CAR-T cells for leukemia, as well as in vivo therapeutics for inherited genetic diseases. The potential is enormous. In addition to the ‘simple’ diseases caused by a single genetic alteration event, the therapeutic strategy, in principle, could also be useful for treating diseases where permanently targeting a disease-related gene is beneficial.”

Dr. David Kimball, Interim Senior Vice President for Research and Economic Development at Rutgers University, added: “Gene editing technology has truly revolutionised how scientists think about their search for better options and outcomes in the treatment of disease. We look forward to advancing the shared goals of further developing this novel base editing platform and improving human health through this collaboration with Horizon.”

ENDS

For further information from Horizon Discovery Group plc, please contact:

Horizon Discovery Group plc

Terry Pizzie, Chief Executive Officer

Tel: +44 (0) 1223 655 580

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott / Matthew Neal / Melissa Gardiner

Tel: +44 (0) 20 3709 5700

Email: 

Base editing

Many human diseases have a simple and known cause, i.e. a single genetic alteration caused through heredity genetics or by an infectious agent.    Examples include genetic diseases such as sickle cell anemia and Duchenne muscular dystrophy, as well as infectious diseases such as AIDS and hepatitis B.  Despite the clear and simple cause, a cure is understandably difficult because the approved drugs, as well as most drugs under development, target a disease-associated target or protein rather than impacting the disease-causing gene itself. This is largely due to a deficiency in understanding of the etiological cause of disease as well as the lack of effective DNA-targeting technology.

CRISPR gene editing technology allows targeted recognition and modification of specific disease-causing DNA sequences in the genes of cells. However, first generation CRISPR technology generates double-strand DNA breaks and often requires disease tissues or cells to have homologous dependent repair activity to achieve optimum therapeutic effect. As double strand DNA breaks are oncogenic in nature and homologous dependent repair activity is by and large absent in diseased tissues, the first generation CRISPR technology arguably has major hurdles to overcome for developing therapeutic vehicles or agents; in particular for developing in vivo therapeutics since it could generate potentially oncogenic DNA breaks and usually requires homology-dependent repair activity which is absent in most disease- affected organs. 

Base Editing has the potential to overcome the issues above by utilising a nuclease-deficient CRISPR protein and an RNA-based recruitment mechanism to guide a non-nuclease DNA modifying enzyme, such as a cytidine deaminase, to the disease-causing gene, where the enzyme effectively corrects or modifies the gene in the disease tissues while minimizing the generation of the potential oncogenic DNA breaks. This allows more accurate editing of genes with reduced negative effects due to unintentional genomic changes. 

About Horizon Discovery Group plc 

Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world leader in gene editing and gene modulation technologies. Horizon designs and engineers cells using its translational genomics platform, a highly precise and flexible suite of DNA editing tools (rAAV, ZFN, CRISPR and Transposon) and, following the acquisition of Dharmacon, Inc., its functional genomics platform comprising gene knockdown (RNAi) and gene expression (cDNA, ORF) tools, for research and clinical applications that advance human health. Horizon's platforms and capabilities enable researchers to alter almost any gene or modulate its function in human or mammalian cell-lines.

Horizon offers an extensive range of catalogue products and related research services to support a greater understanding of the function of genes across all species and the genetic drivers of human disease and the development of personalised molecular, cell and gene therapies. These have been adopted by over 10,000 academic, drug discovery, drug manufacturing and clinical diagnostics customers around the globe, as well as in the Group's own R&D pipeline.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange's AIM market under the ticker HZD

About Rutgers University

Rutgers, The State University of New Jersey, is a leading national research university and the state of New Jersey’s preeminent, comprehensive public institution of higher education. Established in 1766, the university is the eighth oldest higher education institution in the United States. More than 69,000 students and 22,500 full- and part-time faculty and staff learn, work, and serve the public at Rutgers locations across New Jersey and around the world.

EN
28/01/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on HORIZON DISCOVERY GROUP PLC

 PRESS RELEASE

Form 8.3 - The Vanguard Group, Inc.: Horizon Discovery Group plc : AME...

The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Horizon Discovery Group plc : AMENDMENT 18-Nov-2020 / 18:42 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. FORM 8.3 **AMENDMENT TO SECTION 2(a) SUBMITTED ON 3 NOVEMBER 2020** PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")     1. KEY INFORMATION   (a) Full name of discloser: ...

 PRESS RELEASE

Form 8.3 - The Vanguard Group, Inc.: Horizon Discovery Group plc

The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Horizon Discovery Group plc 03-Nov-2020 / 15:04 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")   1. KEY INFORMATION   (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of inte...

 PRESS RELEASE

Horizon Discovery Group plc Results for the Six Months Ended 30 June 2...

Horizon Discovery Group plc Results for the Six Months Ended 30 June 2020 RNS Horizon Discovery Group plcResults for the Six Months Ended 30 June 2020 Cambridge, UK, 17 August 2020: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or “the Company”), a cell engineering company focused on commercialising the application of gene editing and gene modulation to accelerate scientific innovation and biopharmaceutical drug development, today announces its unaudited results for the six months ended 30 June 2020. Group Financial Highlights Reported revenue of £22.4m (HY19:...

 PRESS RELEASE

Horizon Discovery Group plc - Horizon Discovery Group plc Half Year T...

Horizon Discovery Group plc - Horizon Discovery Group plc Half Year Trading Update Horizon Discovery Group plc Half Year Trading Update Business remains robust with sustained recovery to 2019 levels as demand for Horizon’s products and services remains highGroup is confident of a return to growth in H2 2020Capital markets webinar 15:00 BST today – dial in details below Cambridge, UK, 29 July 2020: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or “the Company”), a cell engineering company focused on commercialising the application of gene editing and gene modulation to ...

Horizon Discovery Group: 2 directors bought

Two Directors at Horizon Discovery Group bought 104,850 shares at 101p. The significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch